Which has preferable valuation and earnings, NUVL or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Nuvalent N/A N/A -$425.38M -$6.06 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is NUVL or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Nuvalent's return on equity. Company Net Margins Return on Equity Return on Assets Nuvalent N/A -40.11% -35.43% Enliven Therapeutics N/A -21.04% -20.41%

Does the media favor NUVL or ELVN?

In the previous week, Enliven Therapeutics had 2 more articles in the media than Nuvalent. MarketBeat recorded 7 mentions for Enliven Therapeutics and 5 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Enliven Therapeutics' score of 0.51 indicating that Nuvalent is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvalent 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ELVN or KRYS?

In the previous week, Enliven Therapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Enliven Therapeutics and 6 mentions for Krystal Biotech. Enliven Therapeutics' average media sentiment score of 0.51 beat Krystal Biotech's score of 0.40 indicating that Enliven Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Krystal Biotech 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ELVN or CYTK?

In the previous week, Cytokinetics had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.92 beat Enliven Therapeutics' score of 0.51 indicating that Cytokinetics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 3 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend RGC or ELVN?

Enliven Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 29.07%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Regencell Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Regencell Bioscience 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Enliven Therapeutics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has stronger valuation and earnings, RGC or ELVN?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Regencell Bioscience N/A N/A -$3.58M N/A N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is RGC or ELVN more profitable?

Regencell Bioscience's return on equity of 0.00% beat Enliven Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Regencell Bioscience N/A N/A N/A Enliven Therapeutics N/A -21.04% -20.41%

Does the media prefer RGC or ELVN?

In the previous week, Regencell Bioscience had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.51 beat Regencell Bioscience's score of 0.07 indicating that Enliven Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Regencell Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 13 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, ABVX or ELVN?

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Enliven Therapeutics N/A N/A -$103.69M -$1.67 N/A

Is ABVX or ELVN more profitable?

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Enliven Therapeutics N/A -21.04% -20.41%

Does the media prefer ABVX or ELVN?

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 7 mentions for Enliven Therapeutics and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Enliven Therapeutics' score of 0.51 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Enliven Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Enliven Therapeutics (ELVN) Competitors

$49.12 +1.35 (+2.83%)

Closing price 06/25/2026 04:00 PM Eastern

Extended Trading

$50.00 +0.88 (+1.79%)

As of 04:07 AM Eastern

Compare

ELVN vs. NUVL, KRYS, CYTK, RGC, and ABVX

Should you buy Enliven Therapeutics stock or one of its competitors? MarketBeat compares Enliven Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enliven Therapeutics include Nuvalent (NUVL), Krystal Biotech (KRYS), Cytokinetics (CYTK), Regencell Bioscience (RGC), and Abivax (ABVX). These companies are all part of the "pharmaceutical products" industry.

How does Enliven Therapeutics compare to Nuvalent?

Nuvalent (NASDAQ:NUVL) and Enliven Therapeutics (NASDAQ:ELVN) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

Nuvalent has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

In the previous week, Enliven Therapeutics had 2 more articles in the media than Nuvalent. MarketBeat recorded 7 mentions for Enliven Therapeutics and 5 mentions for Nuvalent. Nuvalent's average media sentiment score of 0.80 beat Enliven Therapeutics' score of 0.51 indicating that Nuvalent is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvalent	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Nuvalent presently has a consensus target price of $127.73, suggesting a potential upside of 3.40%. Enliven Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 29.07%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Nuvalent.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvalent	1 Sell rating(s)	15 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.15
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvalent	N/A	N/A	-$425.38M	-$6.06	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

97.3% of Nuvalent shares are held by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are held by institutional investors. 5.0% of Nuvalent shares are held by insiders. Comparatively, 3.0% of Enliven Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Enliven Therapeutics' return on equity of -21.04% beat Nuvalent's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvalent	N/A	-40.11%	-35.43%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Summary

Enliven Therapeutics beats Nuvalent on 8 of the 13 factors compared between the two stocks.

How does Enliven Therapeutics compare to Krystal Biotech?

Enliven Therapeutics (NASDAQ:ELVN) and Krystal Biotech (NASDAQ:KRYS) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment and risk.

Krystal Biotech has a net margin of 53.92% compared to Enliven Therapeutics' net margin of 0.00%. Krystal Biotech's return on equity of 19.25% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Krystal Biotech	53.92%	19.25%	17.62%

In the previous week, Enliven Therapeutics had 1 more articles in the media than Krystal Biotech. MarketBeat recorded 7 mentions for Enliven Therapeutics and 6 mentions for Krystal Biotech. Enliven Therapeutics' average media sentiment score of 0.51 beat Krystal Biotech's score of 0.40 indicating that Enliven Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Krystal Biotech	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

95.1% of Enliven Therapeutics shares are owned by institutional investors. Comparatively, 86.3% of Krystal Biotech shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by insiders. Comparatively, 13.1% of Krystal Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Krystal Biotech has higher revenue and earnings than Enliven Therapeutics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Krystal Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Krystal Biotech	$389.13M	27.27	$204.83M	$7.48	48.12

Enliven Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Krystal Biotech has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market.

Enliven Therapeutics currently has a consensus target price of $63.40, indicating a potential upside of 29.07%. Krystal Biotech has a consensus target price of $340.56, indicating a potential downside of 5.38%. Given Enliven Therapeutics' higher probable upside, equities research analysts clearly believe Enliven Therapeutics is more favorable than Krystal Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Krystal Biotech	0 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Krystal Biotech beats Enliven Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Enliven Therapeutics compare to Cytokinetics?

Enliven Therapeutics (NASDAQ:ELVN) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, earnings, media sentiment, institutional ownership, valuation, profitability and risk.

Enliven Therapeutics presently has a consensus price target of $63.40, suggesting a potential upside of 29.07%. Cytokinetics has a consensus price target of $100.20, suggesting a potential upside of 24.01%. Given Enliven Therapeutics' higher possible upside, equities research analysts clearly believe Enliven Therapeutics is more favorable than Cytokinetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Cytokinetics	1 Sell rating(s)	3 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	2.86

Enliven Therapeutics has a net margin of 0.00% compared to Cytokinetics' net margin of -784.02%. Cytokinetics' return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enliven Therapeutics	N/A	-21.04%	-20.41%
Cytokinetics	-784.02%	N/A	-52.86%

In the previous week, Cytokinetics had 1 more articles in the media than Enliven Therapeutics. MarketBeat recorded 8 mentions for Cytokinetics and 7 mentions for Enliven Therapeutics. Cytokinetics' average media sentiment score of 0.92 beat Enliven Therapeutics' score of 0.51 indicating that Cytokinetics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cytokinetics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Enliven Therapeutics has higher earnings, but lower revenue than Cytokinetics. Enliven Therapeutics is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A
Cytokinetics	$88.04M	114.20	-$784.96M	-$6.84	N/A

95.1% of Enliven Therapeutics shares are held by institutional investors. 3.0% of Enliven Therapeutics shares are held by insiders. Comparatively, 2.6% of Cytokinetics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Enliven Therapeutics has a beta of 0.29, meaning that its share price is 71% less volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

Cytokinetics beats Enliven Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Enliven Therapeutics compare to Regencell Bioscience?

Regencell Bioscience (NASDAQ:RGC) and Enliven Therapeutics (NASDAQ:ELVN) are both mid-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

Enliven Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 29.07%. Given Enliven Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Enliven Therapeutics is more favorable than Regencell Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Regencell Bioscience	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

0.1% of Regencell Bioscience shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 2.0% of Regencell Bioscience shares are owned by company insiders. Comparatively, 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Regencell Bioscience has a beta of 1.65, indicating that its stock price is 65% more volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, indicating that its stock price is 71% less volatile than the broader market.

In the previous week, Regencell Bioscience had 10 more articles in the media than Enliven Therapeutics. MarketBeat recorded 17 mentions for Regencell Bioscience and 7 mentions for Enliven Therapeutics. Enliven Therapeutics' average media sentiment score of 0.51 beat Regencell Bioscience's score of 0.07 indicating that Enliven Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Regencell Bioscience	0 Very Positive mention(s)	1 Positive mention(s)	13 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Regencell Bioscience's return on equity of 0.00% beat Enliven Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Regencell Bioscience	N/A	N/A	N/A
Enliven Therapeutics	N/A	-21.04%	-20.41%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Regencell Bioscience	N/A	N/A	-$3.58M	N/A	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Summary

Enliven Therapeutics beats Regencell Bioscience on 7 of the 12 factors compared between the two stocks.

How does Enliven Therapeutics compare to Abivax?

Abivax (NASDAQ:ABVX) and Enliven Therapeutics (NASDAQ:ELVN) are both mid-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

Enliven Therapeutics' return on equity of -21.04% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Enliven Therapeutics	N/A	-21.04%	-20.41%

Enliven Therapeutics is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Enliven Therapeutics	N/A	N/A	-$103.69M	-$1.67	N/A

Abivax has a beta of 0.69, suggesting that its stock price is 31% less volatile than the broader market. Comparatively, Enliven Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market.

47.9% of Abivax shares are owned by institutional investors. Comparatively, 95.1% of Enliven Therapeutics shares are owned by institutional investors. 3.0% of Enliven Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abivax currently has a consensus target price of $130.08, suggesting a potential upside of 40.82%. Enliven Therapeutics has a consensus target price of $63.40, suggesting a potential upside of 29.07%. Given Abivax's higher probable upside, analysts clearly believe Abivax is more favorable than Enliven Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
Enliven Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

In the previous week, Enliven Therapeutics had 4 more articles in the media than Abivax. MarketBeat recorded 7 mentions for Enliven Therapeutics and 3 mentions for Abivax. Abivax's average media sentiment score of 0.84 beat Enliven Therapeutics' score of 0.51 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Enliven Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Enliven Therapeutics beats Abivax on 9 of the 14 factors compared between the two stocks.

Get Enliven Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ELVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ELVN vs. The Competition

Export

Metric	Enliven Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.91B	$3.01B	$6.61B	$12.27B
Dividend Yield	N/A	1.77%	2.67%	5.88%
P/E Ratio	-29.41	18.82	26.01	23.97
Price / Sales	N/A	337.03	538.25	99.72
Price / Cash	N/A	56.53	46.33	53.91
Price / Book	6.35	4.12	10.68	6.32
Net Income	-$103.69M	$64.45M	$3.57B	$337.22M
7 Day Performance	8.91%	0.08%	0.80%	-1.23%
1 Month Performance	15.49%	-0.44%	0.23%	-0.63%
1 Year Performance	128.25%	23.45%	30.84%	27.95%

Enliven Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ELVN Enliven Therapeutics	3.1337 of 5 stars	$49.12 +2.8%	$63.40 +29.1%	+128.5%	$2.91B	N/A	N/A	50
NUVL Nuvalent	2.6077 of 5 stars	$123.39 +0.0%	$131.15 +6.3%	+56.2%	$9.75B	N/A	N/A	40	Analyst Downgrade Short Interest Decrease
KRYS Krystal Biotech	2.4294 of 5 stars	$323.37 -0.4%	$329.78 +2.0%	+152.6%	$9.53B	$389.13M	43.23	210
CYTK Cytokinetics	3.1408 of 5 stars	$75.21 +5.4%	$99.30 +32.0%	+144.0%	$9.36B	$88.04M	N/A	250	Analyst Forecast Insider Trade
RGC Regencell Bioscience	0.3615 of 5 stars	$16.73 -2.1%	N/A	-65.5%	$8.27B	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ELVN) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Enliven Therapeutics (ELVN) Competitors

ELVN vs. NUVL, KRYS, CYTK, RGC, and ABVX

How does Enliven Therapeutics compare to Nuvalent?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Summary

How does Enliven Therapeutics compare to Cytokinetics?

Summary

How does Enliven Therapeutics compare to Regencell Bioscience?

Summary

How does Enliven Therapeutics compare to Abivax?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Enliven Therapeutics (ELVN) Competitors

ELVN vs. NUVL, KRYS, CYTK, RGC, and ABVX

How does Enliven Therapeutics compare to Nuvalent?

Which has more risk and volatility, NUVL or ELVN?

Does the media favor NUVL or ELVN?

Do analysts rate NUVL or ELVN?

Which has preferable valuation and earnings, NUVL or ELVN?

Do insiders & institutionals believe in NUVL or ELVN?

Is NUVL or ELVN more profitable?

Summary

How does Enliven Therapeutics compare to Krystal Biotech?

Is ELVN or KRYS more profitable?

Does the media prefer ELVN or KRYS?

Do institutionals and insiders have more ownership in ELVN or KRYS?

Which has better valuation and earnings, ELVN or KRYS?

Which has more risk and volatility, ELVN or KRYS?

Do analysts recommend ELVN or KRYS?

Summary

How does Enliven Therapeutics compare to Cytokinetics?

Do analysts recommend ELVN or CYTK?

Is ELVN or CYTK more profitable?

Does the media prefer ELVN or CYTK?

Which has stronger earnings and valuation, ELVN or CYTK?

Do institutionals & insiders believe in ELVN or CYTK?

Which has more volatility & risk, ELVN or CYTK?

Summary

How does Enliven Therapeutics compare to Regencell Bioscience?

Do analysts recommend RGC or ELVN?

Do insiders & institutionals hold more shares of RGC or ELVN?

Which has more volatility & risk, RGC or ELVN?

Does the media prefer RGC or ELVN?

Is RGC or ELVN more profitable?

Which has stronger valuation and earnings, RGC or ELVN?

Summary

How does Enliven Therapeutics compare to Abivax?

Is ABVX or ELVN more profitable?

Which has higher earnings and valuation, ABVX or ELVN?

Which has more risk and volatility, ABVX or ELVN?

Do institutionals & insiders hold more shares of ABVX or ELVN?

Do analysts rate ABVX or ELVN?

Does the media prefer ABVX or ELVN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ELVN vs. The Competition

Enliven Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools